Shelter Pharma Limited is a **60-year-old** pharmaceutical and nutraceutical powerhouse (established **1965**) specializing in the development and manufacturing of **Ayurvedic, herbal, and natural remedies**. With a portfolio exceeding **300 formulations**, the company bridges traditional herbal wisdom with modern scientific R&D to serve both **Human Healthcare** and **Veterinary/Animal Healthcare** markets. --- ### **Manufacturing Infrastructure & Quality Excellence** The company’s operational backbone is a centralized manufacturing and research hub in Gujarat, designed to meet international safety and quality benchmarks. * **Primary Facility:** Located in **Himatnagar, Gujarat**, the plant occupies a **24,500 sq. ft.** land parcel with a **10,000 sq. ft.** built-up area. * **R&D & Testing:** Features an **FDA-approved R&D facility** and a specialized microbiological laboratory staffed by expert pharmacists to ensure formulation stability and efficacy. * **Certifications & Compliance:** * **GMP, HACCP, and ISO 9001:2015** certified. * **ISO 22000:2018** certified (awarded **November 2025**) for herbal and food supplements. * **FSSAI A+ Rating:** Achieved a high-performance score of **81/86 (94%)** in a **2026** third-party food safety audit. * **Corporate Hub:** A new headquarters was established in **Ahmedabad (May 2024)** to centralize sales, marketing, and institutional relations. * **Sustainability:** Installed a **15 KW Solar Power Plant** in **September 2025** at the Himmatnagar factory. The project has a **25-year** lifespan with an estimated **4-year payback period**, ensuring **21 years** of pure energy cost savings. --- ### **Diversified Product Portfolio & Market Verticals** Shelter Pharma operates across three high-growth segments, focusing on chronic lifestyle conditions, preventive wellness, and livestock productivity. | Vertical | Focus Areas | Key Brands & Products | | :--- | :--- | :--- | | **Human Healthcare** | Kidney stones, Diabetes, Liver dysfunction, Gastrointestinal health, and Hypertension. | **Sherolax**, **Dia-dys**, **Diabetone**, **Livodin-12**, **Hairol** (Hair Oil). | | **Nutraceuticals** | Vitamin deficiencies, bone health, energy, and immunity. | **Allvitamin**, **Joemega** (Omega-3), **D3 Cure**, **Ferrocure**, **FitKick Pro**. | | **Veterinary Care** | Milk yield enhancement, heat induction, pain relief, and poultry nutrition. | **Super Vltamas**, **Lactic Acid Buffer**, **Bypass Fat**, **Liquid Calcium**, **Ecbolic**. | **Recent Innovation Highlights:** * **FitKick Pro (March 2026):** A **zero-sugar** pre-workout powder launched in **three flavors**, targeting the fitness and endurance market via e-commerce platforms like **Amazon**. * **D3 Cure (December 2025):** Launched to address the rising prevalence of Vitamin D deficiency and osteoporosis. * **Core Wellness Range (May 2025):** Introduced **Allvitamins**, **Joemega**, and **Hairol** to the domestic Indian retail market. --- ### **Multi-Channel Sales & Strategic Distribution** The company employs a tiered marketing strategy to penetrate rural, semi-urban, and institutional markets. * **Domestic Reach:** Active in **15 Indian states** with a network of **250 human healthcare distributors** and **50 specialized veterinary distributors** in Gujarat. * **Institutional Partnerships:** * **AMUL:** Secured a major agreement to supply **14 veterinary products** to the Gujarat Co-operative Milk Marketing Federation. * **Verka Dairies:** Qualified the technical evaluation for medicine supply to the Punjab State Cooperative Milk Producers' Federation. * **Cadila Pharmaceuticals:** Strategic tie-up for Ayurvedic welfare solutions in the dairy sector. * **Marketing Channels:** * **OTC Retail:** Supported by a **C&F network** and field sales teams using point-of-purchase (PoP) literature. * **Ethical Retail:** Direct engagement with **Medical Practitioners** through technical brochures. * **Digital:** Growing presence on **reputed online platforms** for the nutraceutical range. --- ### **Global Footprint & Export Momentum** Shelter Pharma is aggressively expanding its international presence, holding product approvals in **Nepal, Egypt, Romania, and Iraq**. **Recent Export Performance (2024–2026):** * **Sudan:** Multiple orders from **Taha Drugs & Chemicals** totaling over **$526,000** for **Allvitamin** and **Joemega**. * **Kuwait:** Secured registration for **FerroCure** and orders for **Beta Glucan Forte** and other supplements worth approx. **₹75 Lakhs** via **Berlin International**. * **UAE:** Orders exceeding **$48,000** from **First Vet Veterinary Medicines** and **$17,700** from **Al-Saqr Agro**. * **French-speaking Markets:** Order worth **$8,750** for **CoughNal** from **BioPharma SA Medical Store**. --- ### **Financial Performance & Capital Structure** The company has demonstrated robust growth, transitioning its capital strategy to support rapid scaling. **Audited Financial Highlights (Standalone):** | Metric | FY 2024-25 | FY 2023-24 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **₹50.66 Crore** | **₹40.02 Crore** | **+26.58%** | | **EBITDA** | **₹10.07 Crore** | **₹8.70 Crore** | **+15.75%** | | **Profit After Tax (PAT)** | **₹7.24 Crore** | **₹6.20 Crore** | **+16.77%** | | **Earnings Per Share (EPS)** | **₹6.26** | **₹5.36** | **+16.79%** | **Capital Allocation Strategy:** * **Fundraising Pivot:** In **June 2025**, the Board replaced a proposed **₹50 Crore Rights Issue** with a more efficient **Preferential Issue** of **Convertible Warrants**. * **Warrant Details:** Issued **91,02,000 warrants** at **₹42.25** (including a **₹32.25 premium**), targeting a total raise of **₹38.45 Crore**. * **Proceeds Utilization:** **85%** allocated to **Working Capital**; **15%** for **General Corporate Purposes**. * **Share Capital:** Authorized capital increased to **₹25 Crore**; Paid-up capital rose to **₹16.61 Crore** by **March 2026** following warrant conversions. * **Shareholder Returns:** Recommended a final dividend of **₹0.35 per share (3.50%)** for FY 2024-25. --- ### **Risk Management & Mitigation** Shelter Pharma manages sectoral risks through disciplined operational controls and diversification. * **Regulatory Compliance:** Mitigated by maintaining **GMP/ISO** standards and rigorous **FDA-approved R&D** protocols. * **Supply Chain Volatility:** Addresses fluctuations in **API/KSM** costs through **diversified sourcing** and strategic inventory planning. * **Working Capital Management:** Focuses on **cycle optimization** to manage the high liquidity requirements of a scaling pharmaceutical business. * **Competitive Pressure:** Counters pricing pressure in branded generics through **product differentiation** and a strengthened **senior leadership team** (Zonal and Export Heads).